End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 CNY | +2.01% | +2.69% | +17.04% |
04-26 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
04-26 | CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.04% | 3.07B | B- | ||
+21.85% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 290B | C+ | ||
+13.68% | 234B | B+ | ||
+3.65% | 198B | B- | ||
-11.12% | 194B | A+ | ||
+8.08% | 167B | C+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600062 Stock
- Ratings China Resources Double-Crane Pharmaceutical Co.,Ltd.